ArticleOpen forum infectious diseases2024
Implementation of Injectable Cabotegravir/Rilpivirine for Treatment of Human Immunodeficiency Virus in Patients With Substance Use Disorders at a Syringe Exchange Clinic.
Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Week 96 Results of Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in People With Substance Use Disorders.Open forum infectious diseases · 2025Trial
- Accelerating Low-Barrier Use of Long-Acting Antiretroviral Therapy to Maximize Impact in People with HIV and Viremia or Adherence Challenges.Current HIV/AIDS reports · 2026Review
- Brief Report: Real-World Uptake and Clinical Outcomes of Long-Acting Injectable Cabotegravir/Rilpivirine in the United States, 2021-2023.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Interactions between long-acting antiretrovirals and opioids: a call for clinical awareness.Clinical microbiology reviews · 2026Review
- Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy.HIV medicine · 2026Article
- Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort.The Journal of antimicrobial chemotherapy · 2025Article
- Integrating harm reduction and addiction care in HIV prevention among persons who inject drugs in the United States-a narrative review.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cabotegravir + rilpivirine (CAB + RPV-LA) is a long-acting antiretroviral therapy (ART) that can be utilized for people with human immunodeficiency virus (HIV) who face barriers to daily ART. Here, we describe the implementation of a program that provides low-barrier access to CAB + RPV-LA for people with HIV and opioid use disorder at a syringe exchange.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.